CTLA4 and hypophysitis: The situation is reversed with checkpoint-inhibitor hypophysitis, where the rate of hypophysitis is higher with CTLA-4 therapy, alone or in combination with PD1 (21), suggesting important pathophysiological differences between the 2 irAEs.